Ansell (FRA:PD1) YoY EBITDA Growth: 82.28% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PD1 Ansell Ltd FRA:PD1
74 GF Score
Price €95.00
GF Value €71.17
! 6 Warning Signs
View Full Analysis

What is Ansell YoY EBITDA Growth?

Ansell FRA:PD1 -0.52% 74 YoY EBITDA Growth is 82.28% as of Jun. 2026. GuruFocus rates FRA:PD1 with a GF Score™ of 74/100 and a GF Value™ of €71.17. The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Ansell's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 82.28%.

Ansell's EBITDA per Share for the six months ended in Jun. 2026 was €5.39.

Ansell YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Ansell's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ansell YoY EBITDA Growth Chart

Ansell Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.92 -7.20 -27.36 6.28 56.15

Ansell Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.64 60.75 -16.47 18.29 82.28
FRA:PD1
74GF Score
Ansell Ltd FRA:PD1
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ansell YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Ansell's YoY EBITDA Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (A: Jun. 2026 )
=(EBITDA per Share (A: Jun. 2026 )-EBITDA per Share (A: Jun. 2025 ))/ | EBITDA per Share (A: Jun. 2025 ) |
=(9.639-6.173)/ | 6.173 |
=56.15 %

Ansell's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(5.39-2.957)/ | 2.957 |
=82.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 82.28% mean?
Ansell (FRA:PD1) has a YoY EBITDA Growth of 82.28% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Ansell and its competitors.
Is Ansell's YoY EBITDA Growth too high?
Ansell's current YoY EBITDA Growth is 82.28%. Overall, Ansell has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Ansell's YoY EBITDA Growth compare to ISRG and BDX?
Ansell's YoY EBITDA Growth of 82.28% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Ansell and its competitors. Ansell's current YoY EBITDA Growth is 82.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ansell stock overvalued right now?
Ansell (FRA:PD1) has a current YoY EBITDA Growth of 82.28%. The stock's GF Value™ is €71.17, compared to a current price of €95.00 — trading 33.5% above its estimated fair value. The current YoY EBITDA Growth is 82.28%. Ansell's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Ansell (FRA:PD1), the current YoY EBITDA Growth is 82.28% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ansell (FRA:PD1) Overvalued in 2026?

Based on GuruFocus' analysis, Ansell stock appears to be overvalued. The current stock price of €95.00 is trading 33.5% above its estimated GF Value™ of €71.17.

Key valuation signals for FRA:PD1:

  • YoY EBITDA Growth: 82.28%
  • GF Value™: €71.17 vs. price of €95.00 (33.5% above fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the FRA:PD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ansell Business Description

Address 678 Victoria Street, Level 3, Richmond, Melbourne, VIC, AUS, 3121
Ansell is a leading supplier of protective gloves for use in healthcare and industrial settings, earning approximately 55% of revenue and operating profit from the healthcare segment and the remainder from the industrial segment. The company holds a large number of patents, and the majority of sales come from its key branded product ranges. Ansell has a global manufacturing and distribution footprint and distributes via key partners as well as directly. Largest sales regions are North America and Europe, Middle East, and Africa. Asia-Pacific and Latin America, combined, are about one-fourth of sales.
74GF Score

Get the complete analysis for FRA:PD1

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€95.00
Price
€71.17
GF Value